Navigation Links
Rigel Initiates Phase 2 Clinical Studies with R343 for Asthma and R333 for Discoid Lupus
Date:9/5/2012

s Foundation of America states that more than 16,000 new cases are diagnosed in the US each year. DLE patients may frequently suffer inflamed disk-shaped sores on the face, chest and scalp, which may cause scarring, swelling and hair loss.  The acute phase of this disorder (and its cousin, SLE) is connected to SYK signaling within the body's immune cascade.  The chronic phase of these disorders is characterized by an abundance of JAK signaling. 

R333 and Discoid Lupus
Currently available treatments for DLE have either poor efficacy or significant toxicities. Rigel's R333 is a potent, topical JAK and SYK inhibitor that is designed to interrupt pivotal inflammatory cascade signals with the potential to prevent or diminish both acute and chronic phases of this disorder. To view Rigel's animation on R333 in DLE, go to www.rigel.com/rigel/discoid_lupus.

About Rigel (www.rigel.com)
Rigel Pharmaceuticals, Inc. is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as muscle disorders. Rigel's pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market its product candidates. Current product development programs include fostamatinib, an oral SYK inhibitor that is in Phase 3 clinical trials for rheumatoid arthritis with its partner AstraZeneca; R343, an inhaled SYK inhibitor for asthma and R333, a topical JAK/SYK inhibitor for discoid lupus – both of which have commenced Phase 2 clinical trials; and R548, an oral JAK3 inhibitor for the treatment of transplant rejection and other immune disorders.

This press release contains "forward-l
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Rigel Announces First Quarter 2012 Financial Results
2. Rigel Advances Asthma Programs: Two Inhaled Drug Candidates Take Aim at Acute and Chronic Lung Disease
3. Rigel Announces Second Quarter 2012 Financial Results
4. Asubio Initiates Landmark Clinical Study in Spinal Cord Injury
5. CSL Behring Initiates Study of Subcutaneous Administration of C1-esterase Inhibitor in Patients with Hereditary Angioedema
6. Isis Initiates Phase 2 Study of ISIS-APOCIIIRx in Patients with Hypertriglyceridemia
7. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
8. Oncos Therapeutics Initiates Phase I Clinical Study of CGTG-102, an Oncolytic Adenovirus for the Treatment of Solid Tumor Cancers
9. MAQUET Initiates Class I Recall of the FLOW-i Anesthesia System
10. Stryker Initiates Voluntary Product Recall of Modular-Neck Stems
11. Inovio Initiates H1N1 Universal Influenza Vaccine Clinical Trial Targeting Over-65 Population, Which Represents 90% of Flu Deaths
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... LAS VEGAS , March 26, 2015 /PRNewswire/ ... worldwide sales agreement with Radlink, Inc., an emerging ... offer real-time image guidance with its hip replacement ... ongoing commitment to help improve patient outcomes, increase ... in conjunction with the 81st annual meeting of ...
(Date:3/26/2015)... 26, 2015  Oxis Biotech, Inc. (OXIS), ... Inc. [OTC: OXIS] and [Euronext Paris: OXI.PA] ... option agreement with the University of Pittsburgh ... Dr. Xiang-Qun Xie , Associate Dean ... School of Pharmacy.  These patents/intellectual properties relate ...
(Date:3/26/2015)... BUENA, N.J. , March 26, 2015 ... New Jersey based specialty generic pharmaceutical company, ... drug application (ANDA) to the U.S. Food and Drug ... number of ANDA submissions now pending at the FDA ... and CEO of the Company, commented, "On March 2, ...
Breaking Medicine Technology:DePuy Synthes Companies Announces Exclusive Agreement With Radlink To Help Address Key Challenges In Hip Replacement 2DePuy Synthes Companies Announces Exclusive Agreement With Radlink To Help Address Key Challenges In Hip Replacement 3Oxis Biotech Executes Option Agreement to Certain Patents/Intellectual Properties Owned by the University of Pittsburgh 2Oxis Biotech Executes Option Agreement to Certain Patents/Intellectual Properties Owned by the University of Pittsburgh 3IGI Laboratories, Inc. Announces First ANDA Submission Of 2015 2
(Date:3/26/2015)... “The SWEET Act is an important step ... available and help parents who are working to reduce sugar ... approach to support public health, and we will continue to ... health of all families,” said Dr. Jane Delgado President and ... introduction of the Sugar-Sweetened Beverage Tax (SWEET) Act by Congresswoman ...
(Date:3/26/2015)... 26, 2015 The Life Support ... to Hyperbaric Medicine” course, which is accredited by ... and the National Board of Diving & Hyperbaric ... course 4 times a year at several of ... tri-state region; registration is available on-line at: ...
(Date:3/26/2015)... The National League for Nursing, and ... has announced its partnership with Questionmark®, a supplier ... to accurately and securely measure knowledge, skills, and ... Questionmark’s state-of-the-art software and a custom-built portal, ... of the seventy-five to one hundred thousand exams ...
(Date:3/26/2015)... 26, 2015 In preparation for the ... Revolution, founded by Samir Becic, has issued “report ... personal health and fitness, as well as their promotion ... list includes Sen. Ted Cruz, who has officially announced ... all other politicians who have shown interest in running ...
(Date:3/26/2015)... 26, 2015 Zane Benefits, the leader ... a new eBook, “The Comprehensive Guide To Interviewing For ... is the most important aspect of the hiring process. ... hiring the right way, possibly resulting in thousands of ... arduous undertaking, yet it’s essential to the success of ...
Breaking Medicine News(10 mins):Health News:National Alliance for Hispanic Health Statement on Introduction of SWEET Act in 114th Congress 2Health News:The Life Support Technologies Group (LST) Conducted its 30th Accredited “Introduction to Hyperbaric Medicine” Course for Health Care Professionals 2Health News:The Life Support Technologies Group (LST) Conducted its 30th Accredited “Introduction to Hyperbaric Medicine” Course for Health Care Professionals 3Health News:The Life Support Technologies Group (LST) Conducted its 30th Accredited “Introduction to Hyperbaric Medicine” Course for Health Care Professionals 4Health News:NLN Testing Services Announces Improved Delivery and Analytics Software and Newly Developed and Revised Exams 2Health News:How the Candidates for the 2016 Presidential Election Rank in Health and Fitness 2Health News:How the Candidates for the 2016 Presidential Election Rank in Health and Fitness 3Health News:Zane Benefits Announces: New eBook: The Comprehensive Guide To Interviewing For Your Small Business 2
... Orthopedic,Group, Inc. (NYSE: HGR ) announces record revenue ... $0.18 per diluted share, for the quarter ended,September 30, ... increase in,net sales, a 24.6% increase in net income, ... pro-forma results for the third quarter of 2006. The,pro-forma ...
... the inaugural Mississippi Blues Marathon and,Half-Marathon, scheduled for January 5, 2008. Prize money will be awarded,in the following categories ... Male Female 1st Place $4,000 ... 3,000 3rd Place 2,000 2,000 4th ... 1,000 1,000, Wheelchair $500 ...
... Md., Oct. 29 The Cystic Fibrosis,Foundation was selected ... USA Track & Field (USATF), the national governing body ... The CF Foundation was honored for its largest fundraising ... nearly $32 million in 2006,and for other road races, ...
... are diagnosed with breast cancer at a younger age ... than Caucasian women, a Yale School of Medicine researcher ... Therapeutic Radiology and Oncology meeting in Los Angeles, ... Yale Cancer Center member, said her results were based ...
... important new research on the topics of cardiovascular ... kidney injury, racial and ethnic disparities of kidney ... being presented during the American Society of Nephrology,s ... Francisco at a policy-centered news briefing on Saturday, ...
... small, short-term trial is unlikely to quiet Natrecor,s critics , , ... the safety of Natrecor, a widely used heart failure medication, ... , Critics have charged that Natrecor, which costs about $500 ... may raise their risk of kidney failure and death. , ...
Cached Medicine News:Health News:Hanger Orthopedic Group, Inc. Announces Record Revenue of $162.3 Million and 20% Growth in Earnings Per Share for the Quarter Ended September 30, 2007 2Health News:Hanger Orthopedic Group, Inc. Announces Record Revenue of $162.3 Million and 20% Growth in Earnings Per Share for the Quarter Ended September 30, 2007 3Health News:Hanger Orthopedic Group, Inc. Announces Record Revenue of $162.3 Million and 20% Growth in Earnings Per Share for the Quarter Ended September 30, 2007 4Health News:Hanger Orthopedic Group, Inc. Announces Record Revenue of $162.3 Million and 20% Growth in Earnings Per Share for the Quarter Ended September 30, 2007 5Health News:Hanger Orthopedic Group, Inc. Announces Record Revenue of $162.3 Million and 20% Growth in Earnings Per Share for the Quarter Ended September 30, 2007 6Health News:Hanger Orthopedic Group, Inc. Announces Record Revenue of $162.3 Million and 20% Growth in Earnings Per Share for the Quarter Ended September 30, 2007 7Health News:Hanger Orthopedic Group, Inc. Announces Record Revenue of $162.3 Million and 20% Growth in Earnings Per Share for the Quarter Ended September 30, 2007 8Health News:Hanger Orthopedic Group, Inc. Announces Record Revenue of $162.3 Million and 20% Growth in Earnings Per Share for the Quarter Ended September 30, 2007 9Health News:Cystic Fibrosis Foundation Named Charitable Organization of the Year by USA Track & Field 2Health News:Breast cancer is more aggressive in African-American women 2Health News:Study Supports Controversial Heart Failure Drug 2Health News:Study Supports Controversial Heart Failure Drug 3Health News:Study Supports Controversial Heart Failure Drug 4
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: